Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone

Ozgul Muneyyirci-Delale, Julie R. Kaplan, Ibrahim Joulak, Lianfu Yang, Hans Von Gizycki, Vijaya L. Nacharaju

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To assess the effect of glucophage, magnesium oxide and spironolactone in altering free fatty acids (FFAs), 36 PCOS women were randomly divided into three groups. Group 1 (n=14) was treated with 500mg glucophage po bid, group 2 (n=10) was treated with 400mg magnesium oxide po bid and group 3 (n=12) was treated with 50mg spironolactone po bid for 12 weeks. A glucose tolerance test with 75g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2h for insulin, glucose, FFA and aldosterone. Amount of FFA before and after treatment were compared by repeated measure ANOVA and represented as area under the curve. FFA levels before treatment were 0.83±0.23, 0.77±0.15 and 0.85±0.28 and after treatment were 0.77±0.48, 0.71±0.18 and 0.66±0.25 for glucophage, magnesium oxide and spironolactone-treated patients, respectively. The FFA levels were unchanged in the groups treated with glucophage and magnesium oxide but were significantly (p<0.03) decreased in the group treated with spironolactone. Since FFAs are known to be involved in the development of insulin resistance, these results suggest that spironolactone may be useful for lowering insulin resistance in PCOS patients.

Original languageEnglish (US)
Pages (from-to)474-477
Number of pages4
JournalGynecological Endocrinology
Volume29
Issue number5
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Magnesium Oxide
Spironolactone
Metformin
Nonesterified Fatty Acids
Serum
Insulin Resistance
Glycyrrhetinic Acid
Glucose
Therapeutics
Glucose Tolerance Test
Aldosterone
Area Under Curve
Analysis of Variance
Insulin

Keywords

  • Free fatty acid
  • Polycystic ovary syndrome (PCOS)
  • Spironolactone

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Obstetrics and Gynecology

Cite this

Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone. / Muneyyirci-Delale, Ozgul; Kaplan, Julie R.; Joulak, Ibrahim; Yang, Lianfu; Von Gizycki, Hans; Nacharaju, Vijaya L.

In: Gynecological Endocrinology, Vol. 29, No. 5, 05.2013, p. 474-477.

Research output: Contribution to journalArticle

Muneyyirci-Delale, Ozgul ; Kaplan, Julie R. ; Joulak, Ibrahim ; Yang, Lianfu ; Von Gizycki, Hans ; Nacharaju, Vijaya L. / Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone. In: Gynecological Endocrinology. 2013 ; Vol. 29, No. 5. pp. 474-477.
@article{f57c84a4f1534b1aa402d4f89b36e2ea,
title = "Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone",
abstract = "To assess the effect of glucophage, magnesium oxide and spironolactone in altering free fatty acids (FFAs), 36 PCOS women were randomly divided into three groups. Group 1 (n=14) was treated with 500mg glucophage po bid, group 2 (n=10) was treated with 400mg magnesium oxide po bid and group 3 (n=12) was treated with 50mg spironolactone po bid for 12 weeks. A glucose tolerance test with 75g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2h for insulin, glucose, FFA and aldosterone. Amount of FFA before and after treatment were compared by repeated measure ANOVA and represented as area under the curve. FFA levels before treatment were 0.83±0.23, 0.77±0.15 and 0.85±0.28 and after treatment were 0.77±0.48, 0.71±0.18 and 0.66±0.25 for glucophage, magnesium oxide and spironolactone-treated patients, respectively. The FFA levels were unchanged in the groups treated with glucophage and magnesium oxide but were significantly (p<0.03) decreased in the group treated with spironolactone. Since FFAs are known to be involved in the development of insulin resistance, these results suggest that spironolactone may be useful for lowering insulin resistance in PCOS patients.",
keywords = "Free fatty acid, Polycystic ovary syndrome (PCOS), Spironolactone",
author = "Ozgul Muneyyirci-Delale and Kaplan, {Julie R.} and Ibrahim Joulak and Lianfu Yang and {Von Gizycki}, Hans and Nacharaju, {Vijaya L.}",
year = "2013",
month = "5",
doi = "10.3109/09513590.2013.769515",
language = "English (US)",
volume = "29",
pages = "474--477",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone

AU - Muneyyirci-Delale, Ozgul

AU - Kaplan, Julie R.

AU - Joulak, Ibrahim

AU - Yang, Lianfu

AU - Von Gizycki, Hans

AU - Nacharaju, Vijaya L.

PY - 2013/5

Y1 - 2013/5

N2 - To assess the effect of glucophage, magnesium oxide and spironolactone in altering free fatty acids (FFAs), 36 PCOS women were randomly divided into three groups. Group 1 (n=14) was treated with 500mg glucophage po bid, group 2 (n=10) was treated with 400mg magnesium oxide po bid and group 3 (n=12) was treated with 50mg spironolactone po bid for 12 weeks. A glucose tolerance test with 75g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2h for insulin, glucose, FFA and aldosterone. Amount of FFA before and after treatment were compared by repeated measure ANOVA and represented as area under the curve. FFA levels before treatment were 0.83±0.23, 0.77±0.15 and 0.85±0.28 and after treatment were 0.77±0.48, 0.71±0.18 and 0.66±0.25 for glucophage, magnesium oxide and spironolactone-treated patients, respectively. The FFA levels were unchanged in the groups treated with glucophage and magnesium oxide but were significantly (p<0.03) decreased in the group treated with spironolactone. Since FFAs are known to be involved in the development of insulin resistance, these results suggest that spironolactone may be useful for lowering insulin resistance in PCOS patients.

AB - To assess the effect of glucophage, magnesium oxide and spironolactone in altering free fatty acids (FFAs), 36 PCOS women were randomly divided into three groups. Group 1 (n=14) was treated with 500mg glucophage po bid, group 2 (n=10) was treated with 400mg magnesium oxide po bid and group 3 (n=12) was treated with 50mg spironolactone po bid for 12 weeks. A glucose tolerance test with 75g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2h for insulin, glucose, FFA and aldosterone. Amount of FFA before and after treatment were compared by repeated measure ANOVA and represented as area under the curve. FFA levels before treatment were 0.83±0.23, 0.77±0.15 and 0.85±0.28 and after treatment were 0.77±0.48, 0.71±0.18 and 0.66±0.25 for glucophage, magnesium oxide and spironolactone-treated patients, respectively. The FFA levels were unchanged in the groups treated with glucophage and magnesium oxide but were significantly (p<0.03) decreased in the group treated with spironolactone. Since FFAs are known to be involved in the development of insulin resistance, these results suggest that spironolactone may be useful for lowering insulin resistance in PCOS patients.

KW - Free fatty acid

KW - Polycystic ovary syndrome (PCOS)

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=84875837459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875837459&partnerID=8YFLogxK

U2 - 10.3109/09513590.2013.769515

DO - 10.3109/09513590.2013.769515

M3 - Article

C2 - 23461841

AN - SCOPUS:84875837459

VL - 29

SP - 474

EP - 477

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 5

ER -